139 related articles for article (PubMed ID: 8200572)
1. Diagnostic pitfall; interpretation of CA 19-9 concentrations in the presence of hepatic dysfunction.
Pearce S; Thornes H; Carr D; Tanner A
Gut; 1994 May; 35(5):707-8. PubMed ID: 8200572
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1992 May; 65(5):731-4. PubMed ID: 1316775
[TBL] [Abstract][Full Text] [Related]
3. A prospective study of the value of imaging, serum markers and their combination in the diagnosis of pancreatic carcinoma in symptomatic patients.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1992; 12(6B):2309-14. PubMed ID: 1295478
[TBL] [Abstract][Full Text] [Related]
4. Does serum CAR-3 play a role in pancreatic cancer diagnosis?
Basso D; Panozzo MP; Fabris C; Meggiato T; Faggian D; Fogar P; Scalon P; Del Favero G; Plebani M; Burlina A
Oncology; 1991; 48(1):22-5. PubMed ID: 1987495
[TBL] [Abstract][Full Text] [Related]
5. Serum CA 242: the search for a valid marker of pancreatic cancer.
Ventrucci M; Ubalducci GM; Cipolla A; Panella MA; Ligabue A
Clin Chem Lab Med; 1998 Mar; 36(3):179-84. PubMed ID: 9589807
[TBL] [Abstract][Full Text] [Related]
6. Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
J Cancer Res Clin Oncol; 1994; 120(8):494-7. PubMed ID: 8207049
[TBL] [Abstract][Full Text] [Related]
7. ERCP combined with tumor markers in differential diagnosis of pancreatic cancer and pseudotumor-like pancreatitis.
Luo B; Peng F; Hong M; Su S; Fang C; Yang X; Xia G; Li B
J BUON; 2019; 24(4):1568-1573. PubMed ID: 31646810
[TBL] [Abstract][Full Text] [Related]
8. Tumour antigens CA 195 and CA 19-9 in pancreatic juice and serum for the diagnosis of pancreatic carcinoma.
Hyöty M; Hyöty H; Aaran RK; Airo I; Nordback I
Eur J Surg; 1992 Mar; 158(3):173-9. PubMed ID: 1356458
[TBL] [Abstract][Full Text] [Related]
9. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
[TBL] [Abstract][Full Text] [Related]
10. [Use of the CA 19-9 tumor marker in the diagnosis of pancreatic carcinoma].
Kausitz J; Lesný P; Belan V
Bratisl Lek Listy; 1993 Apr; 94(4):201-3. PubMed ID: 8353764
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of TPS, TPA and CA 19-9 measurement in pancreatic cancer.
Plebani M; Basso D; Del Favero G; Ferrara C; Meggiato T; Fogar P; Mangano F; Ricciardi G; Burlina A
Oncology; 1993; 50(6):436-40. PubMed ID: 8233283
[TBL] [Abstract][Full Text] [Related]
12. [Blood CA 19-9 in the diagnosis of carcinoma of the pancreas: a critical approach].
Angonese C; Basso D; Del Favero G; Fabris C; Tremolada C; Plebani M; Burlina A; Naccarato R
Ann Ital Med Int; 1987; 2(2):138-42. PubMed ID: 3275279
[No Abstract] [Full Text] [Related]
13. [Value of plasma testosterone, carcinoembryonic antigen and CA 19-9 in the differential diagnosis of pancreatic carcinoma and chronic pancreatitis].
Jurkowska G; Kulpa J; Skrodzka D; Rogowski F
Pol Arch Med Wewn; 1992 Nov; 88(5):302-9. PubMed ID: 1300550
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study.
Adamek HE; Albert J; Breer H; Weitz M; Schilling D; Riemann JF
Lancet; 2000 Jul; 356(9225):190-3. PubMed ID: 10963196
[TBL] [Abstract][Full Text] [Related]
15. [Autoimmune pancreatitis in a patient with ulcerative colitis simulating a pancreatic tumor].
Bor R; Farkas K; Bálint A; Wittmann T; Nagy F; Tiszlavicz L; Molnár T; Szepes Z
Orv Hetil; 2014 Jun; 155(25):1000-4. PubMed ID: 24936576
[TBL] [Abstract][Full Text] [Related]
16. [The use of the carbohydrate antigen CA-19-9, the carcinoembryonic antigen and alpha fetoprotein in the diagnosis of pancreatic cancer].
Skvortsov SV; Kalinin AV; Lytsar' BN
Vestn Ross Akad Med Nauk; 1993; (4):47-9. PubMed ID: 7687486
[TBL] [Abstract][Full Text] [Related]
17. The reliability of highly elevated CA 19-9 levels.
Osswald BR; Klee FE; Wysocki S
Dis Markers; 1993 Dec; 11(5-6):275-8. PubMed ID: 8082316
[TBL] [Abstract][Full Text] [Related]
18. The influence of cholestasis on CA 50 and CA 242 in pancreatic cancer and benign biliopancreatic diseases.
Pålsson B; Masson P; Andrén-Sandberg A
Scand J Gastroenterol; 1993 Nov; 28(11):981-7. PubMed ID: 8284635
[TBL] [Abstract][Full Text] [Related]
19. CAR-3 and CA 19-9 serum levels in pancreatic cancer: any differences between two epitopes of the same mucin-like glycoprotein?
Meggiato T; Basso D; Fabris C; Fogar P; Panozzo MP; Plebani M; Faggian D; Scalon P; Ferrara C; Del Favero G
Dis Markers; 1990; 8(4):171-7. PubMed ID: 1708317
[TBL] [Abstract][Full Text] [Related]
20. Novel tumour markers: a diagnostic role in pancreatic cancer?
Roulston JE
Br J Cancer; 1994 Sep; 70(3):389-90. PubMed ID: 8080718
[No Abstract] [Full Text] [Related]
[Next] [New Search]
